Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

6.940 -0.200 (-2.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week
The cancer-focused biotech has a bright future, according to one pundit. 
Via The Motley Fool
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Preview: Relay Therapeutics's Earnings
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. 
Via Benzinga
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire
Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Relay (RLAY) Q2 Loss Narrows 41%
Via The Motley Fool
Topics Intellectual Property
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Company to host conference call on Wednesday, December 11, 2024 at 7am ET 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Why Relay Therapeutics Plummeted by Nearly 14% Today
Investors weren't happy with the company's latest effort at capital-raising. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.